{"id":"https://openalex.org/W4310103491","doi":"https://doi.org/10.1182/blood-2022-169817","title":"iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma","display_name":"iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310103491","doi":"https://doi.org/10.1182/blood-2022-169817"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-169817","doi":"https://doi.org/10.1182/blood-2022-169817","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-169817","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5066354365","display_name":"Rina M. Mbofung","orcid":"https://orcid.org/0000-0003-3872-3143","observed_orcids":["https://orcid.org/0000-0003-3872-3143"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rina M Mbofung","raw_affiliation_strings":["1Fate Therapeutics Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043971549","display_name":"Xingyue Zong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xingyue Zong","raw_affiliation_strings":["2Fate Therapeutics, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Fate Therapeutics, Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087672318","display_name":"Erika Varady","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erika Varady","raw_affiliation_strings":["1Fate Therapeutics Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088704373","display_name":"Alan M Williams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alan M Williams","raw_affiliation_strings":["1Fate Therapeutics Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033725649","display_name":"Ken L. Hayama","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ken L Hayama","raw_affiliation_strings":["1Fate Therapeutics Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113925603","display_name":"Yijia Pan","orcid":"https://orcid.org/0009-0009-2136-3891","observed_orcids":["https://orcid.org/0009-0009-2136-3891"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yijia Pan","raw_affiliation_strings":["1Fate Therapeutics Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028619599","display_name":"Sushil Devkota","orcid":"https://orcid.org/0000-0002-6886-1929","observed_orcids":["https://orcid.org/0000-0002-6886-1929"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sushil Devkota","raw_affiliation_strings":["1Fate Therapeutics Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025807763","display_name":"Brian C. Groff","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian Groff","raw_affiliation_strings":["1Fate Therapeutics Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008475291","display_name":"Miguel Meza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Miguel Meza","raw_affiliation_strings":["1Fate Therapeutics Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114027043","display_name":"Thomas Dailey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Dailey","raw_affiliation_strings":["1Fate Therapeutics Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103253648","display_name":"Tom Lee","orcid":"https://orcid.org/0000-0003-0805-4006","observed_orcids":["https://orcid.org/0000-0003-0805-4006"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tom Lee","raw_affiliation_strings":["1Fate Therapeutics Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fate Therapeutics Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088108919","display_name":"Lilly  M. Wong","orcid":"https://orcid.org/0000-0001-7460-8658","observed_orcids":["https://orcid.org/0000-0001-7460-8658"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lilly Wong","raw_affiliation_strings":["2Fate Therapeutics, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Fate Therapeutics, Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101974554","display_name":"Sarah Cooley","orcid":"https://orcid.org/0000-0001-8953-6730","observed_orcids":["https://orcid.org/0000-0001-8953-6730"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Cooley","raw_affiliation_strings":["2Fate Therapeutics, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Fate Therapeutics, Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011430525","display_name":"Ryan Bjordahl","orcid":"https://orcid.org/0000-0001-9277-3155","observed_orcids":["https://orcid.org/0000-0001-9277-3155"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan Bjordahl","raw_affiliation_strings":["3Fate Therapeutics, San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Fate Therapeutics, San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109787025","display_name":"Jode Goodridge","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jode P Goodridge","raw_affiliation_strings":["2Fate Therapeutics, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Fate Therapeutics, Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070964738","display_name":"Bahram Bob Valamehr","orcid":"https://orcid.org/0000-0002-5917-3585","observed_orcids":["https://orcid.org/0000-0002-5917-3585"]},"institutions":[{"id":"https://openalex.org/I4210155835","display_name":"Fate Therapeutics (United States)","ror":"https://ror.org/04p6jwd33","country_code":"US","type":"company","lineage":["https://openalex.org/I4210155835"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bahram Valamehr","raw_affiliation_strings":["2Fate Therapeutics, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Fate Therapeutics, Inc., San Diego, CA","institution_ids":["https://openalex.org/I4210155835"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210155835"],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.2293,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.428445,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"7388","last_page":"7389"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.7567999958992004,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.7567999958992004,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.14390000700950623,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.024700000882148743,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ipsc-derived-nk-cells","display_name":"iPSC-derived NK cells","score":0.9279999732971191},{"id":"https://openalex.org/keywords/daratumumab","display_name":"daratumumab","score":0.8299999833106995},{"id":"https://openalex.org/keywords/anti-cd38-monoclonal-antibody","display_name":"anti-CD38 monoclonal antibody","score":0.9409999847412109},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.9160000085830688},{"id":"https://openalex.org/keywords/fratricide","display_name":"fratricide","score":0.9520000219345093},{"id":"https://openalex.org/keywords/cd16","display_name":"CD16","score":0.546999990940094},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.8510000109672546},{"id":"https://openalex.org/keywords/off-the-shelf-cell-therapy","display_name":"off-the-shelf cell therapy","score":0.7699999809265137}],"concepts":[{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.8719528913497925},{"id":"https://openalex.org/C159912055","wikidata":"https://www.wikidata.org/wiki/Q14885119","display_name":"CD38","level":4,"score":0.8192209005355835},{"id":"https://openalex.org/C2781119759","wikidata":"https://www.wikidata.org/wiki/Q5222113","display_name":"Daratumumab","level":4,"score":0.6289853453636169},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5995451211929321},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.5642687082290649},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5495681166648865},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.514320969581604},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.39633601903915405},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.37164050340652466},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.36007142066955566},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.1832357943058014},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.17380306124687195},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.15162694454193115},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.10949060320854187},{"id":"https://openalex.org/C10205521","wikidata":"https://www.wikidata.org/wiki/Q4035578","display_name":"CD34","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-169817","doi":"https://doi.org/10.1182/blood-2022-169817","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-169817","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.6000000238418579,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1600286956","https://openalex.org/W2593871724","https://openalex.org/W2764340845","https://openalex.org/W3176072338","https://openalex.org/W2343368748","https://openalex.org/W3199790558","https://openalex.org/W4361945426","https://openalex.org/W4361951970","https://openalex.org/W2588049026","https://openalex.org/W3004787422"],"abstract_inverted_index":{"Anti-CD38":[0],"therapeutic":[1,14,72,623],"monoclonal":[2],"antibodies":[3],"(mAbs)":[4],"such":[5],"as":[6,41,108,355,620],"daratumumab":[7],"(dara)":[8],"have":[9],"shown":[10],"wide":[11],"application":[12],"and":[13,63,85,172,184,347,374,427,443,481,496,510,518,522,539,550],"benefit":[15],"for":[16,38,59,112,120,169,255,637],"Multiple":[17],"Myeloma":[18],"(MM)":[19],"patients.":[20],"However,":[21,397],"antibody-dependent":[22],"cell-mediated":[23],"cytotoxicity":[24],"(ADCC),":[25],"a":[26,71,139,151,163,199,621],"critical":[27],"mechanism":[28],"of":[29,79,83,101,115,132,175,201,247,277,285,321,401,478,506,534,567,629],"action":[30],"associated":[31],"with":[32,45,137,161,215,261,343,363,451,475,525,536,559,617],"many":[33],"mAbs,":[34,88],"is":[35],"not":[36,581],"realized":[37],"anti-CD38":[39,66,87,180,219,291,322,562,568,590,618],"mAbs":[40],"the":[42,46,76,80,99,109,113,206,274,283,303,307,319,384,467,476,565,585,597,608,627,635],"effector":[43],"cells":[44,119,252,405,416,445,521,553,579,601,616],"potential":[47,609],"to":[48,65,156,178,185,192,209,264,279,299,305,332,370,382,489,574,610],"elicit":[49],"ADCC,":[50],"namely":[51],"natural":[52],"killer":[53],"(NK)":[54],"cells,":[55,499],"are":[56],"also":[57,294],"positive":[58],"CD38":[60,176,408,453],"surface":[61],"expression":[62,177],"succumb":[64],"mAb-mediated":[67,220],"fratricide.":[68],"To":[69,124,317,464],"develop":[70],"strategy":[73],"that":[74,588],"captures":[75],"full":[77],"breadth":[78],"anti-tumor":[81],"capacity":[82],"dara":[84,216,228,236,258,265,364,391,402,438],"other":[86],"we":[89,195,287,328],"utilized":[90],"our":[91],"induced":[92],"pluripotent":[93],"stem":[94],"cell":[95,122,130,188,234,386,640],"(iPSC)":[96],"platform,":[97],"where":[98,249],"generation":[100],"precisely":[102],"engineered":[103,117,474],"master":[104,140],"iPSC":[105,141],"lines":[106],"serve":[107],"starting":[110],"material":[111],"manufacture":[114],"uniformly":[116],"immune":[118],"off-the-shelf":[121,612],"therapies.":[123],"generate":[125],"an":[126,543],"iPSC-derived":[127,613],"NK":[128,187,233,385,404,442,538,552,578,600,615],"(iNK)":[129],"capable":[131],"maximizing":[133],"ADCC":[134,158,212,630],"in":[135,159,198,243,282,314,361,388,437,449,460,523,529,544,584,639],"combination":[136,160,362,524],"dara,":[138,286,526],"line":[142],"(termed":[143],"FT538)":[144],"was":[145,259,393,458,472,594],"created":[146],"containing":[147],"three":[148],"unique":[149,207,275],"edits;":[150],"high-affinity,":[152],"non-cleavable":[153],"CD16":[154],"(hnCD16)":[155],"potentiate":[157],"mAb,":[162,591],"recombinant":[164],"IL-15":[165],"receptor":[166],"fusion":[167],"(IL-15RF)":[168],"cytokine-autonomous":[170],"persistence":[171,528],"importantly,":[173],"deletion":[174],"prevent":[179],"mAb":[181,292,323,569,619],"mediated":[182],"fratricide":[183,221,281],"enhance":[186],"fitness.":[189],"In":[190,411,435,542,564,603],"addition":[191],"previous":[193],"studies,":[194],"show":[196],"here":[197],"variety":[200],"preclinical":[202],"models,":[203],"FT538":[204,226,262,269,278,471,502,549,572,593],"has":[205],"ability":[208,276],"exhibit":[210],"potent":[211],"when":[213,257],"combined":[214,260],"by":[217,423,493,516,596],"avoiding":[218],"(MM1s":[222],"tumor":[223,245],"remaining":[224],"after":[225,231,341,398,418],"+":[227,235],"=":[229,237,358,378],"16%,":[230],"primary":[232],"61%).":[238],"Similar":[239],"results":[240],"were":[241,253,420,446,554,580],"seen":[242],"xenograft":[244],"models":[246,532],"MM,":[248],"established":[250,273],"MM1S":[251],"controlled":[254],"growth":[256],"compared":[263],"alone":[266,270],"(p<0.001)":[267],"or":[268,301,335,360,560,633],"(p<0.001).":[271,602],"Having":[272],"avoid":[280],"presence":[284,566],"next":[288],"investigated":[289],"whether":[290],"could":[293],"deplete":[295],"alloreactive":[296],"CD38+":[297,395,422],"lymphocytes":[298],"reduce":[300],"eliminate":[302,466],"need":[304,636],"administer":[306],"unfavorable":[308],"lymphodepleting":[309],"conditioning":[310],"(LDC)":[311],"currently":[312],"used":[313,329],"cellular":[315],"immunotherapy.":[316],"evaluate":[318],"effect":[320],"on":[324,469],"host":[325],"lymphocyte":[326],"reconstitution":[327],"flow":[330],"cytometry":[331],"characterize":[333],"PBMCs":[334],"marrow":[336,462],"collected":[337],"from":[338],"MM":[339],"patients":[340,389,413,440],"LDC":[342,371,383,419,638],"cytoxan":[344],"300":[345],"mg/m2":[346,350],"fludarabine":[348],"30":[349],"x":[351],"3":[352],"days":[353],"either":[354],"monotherapy":[356,412],"(N":[357],"4)":[359],"16":[365],"mg/kg":[366],"1":[367,399],"week":[368],"prior":[369],"(Day":[372],"-11)":[373],"weekly":[375],"thereafter":[376],"(n":[377],"3)":[379],"(NCT05182073).":[380],"Prior":[381],"population":[387],"without":[390,561],"treatment":[392],"highly":[394],"(80-90%).":[396],"dose":[400],"patient":[403],"expressed":[406],"reduced":[407,448],"(all":[409],"<20%).":[410],"CD8+":[414,494,517],"T":[415,444,498,520,540],"reconstituting":[417,441],"predominantly":[421],"Day":[424,431],"8":[425],"(80-90%)":[426],"remained":[428],"so":[429],"through":[430],"29":[432],"(Figure":[433],"1).":[434],"contrast,":[436],"treated":[439],"significantly":[447],"number":[450],"low":[452],"expression.":[454],"The":[455],"same":[456],"pattern":[457],"observed":[459],"bone":[461],"lymphocytes.":[463],"fully":[465],"dependency":[468],"LDC,":[470],"further":[473],"knockout":[477],"beta-2":[479],"macroglobulin":[480],"class":[482,508,511],"II":[483,512],"major":[484],"histocompatibility":[485],"complex":[486],"transactivator":[487],"(B2M/CIITA-null)":[488],"render":[490],"it":[491],"undetectable":[492],"cytotoxic":[495],"CD4+":[497,519],"respectively.":[500],"B2M/CIITA-null":[501,548,571,592],"showed":[503],"complete":[504],"loss":[505],"HLA":[507],"I":[509],"expression,":[513],"became":[514],"unrecognizable":[515],"displayed":[527],"various":[530],"allogeneic":[531,537,546,551,577,599],"consisting":[533],"co-culture":[535],"cells.":[541],"vivo":[545],"model,":[547],"co-infused":[555],"into":[556],"NOG-IL15":[557],"mice":[558],"mAb.":[563],"treatment,":[570],"continued":[573],"persist":[575],"while":[576,583,631],"detected,":[582],"study":[586],"arm":[587],"lacked":[589],"eliminated":[595],"persisting":[598],"summary,":[604],"these":[605],"data":[606],"demonstrate":[607],"combine":[611],"CD38-null":[614],"novel":[622],"strategy,":[624],"uniquely":[625],"demonstrating":[626],"potentiating":[628],"reducing":[632],"eliminating":[634],"therapy.":[641],"Figure":[642],"1View":[643,646],"largeDownload":[644,647],"PPTFigure":[645],"PPT":[648],"Close":[649],"modal":[650]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}